DrugPatentWatch Database Preview

COMBIVENT Drug Profile

  Purchase this report

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Combivent patents expire, and when can generic versions of Combivent launch?

Combivent is a drug marketed by Boehringer Ingelheim and is included in two NDAs. There are eleven patents protecting this drug.

The generic ingredient in COMBIVENT is albuterol sulfate; ipratropium bromide. There are thirty-eight drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the albuterol sulfate; ipratropium bromide profile page.

Summary for COMBIVENT

US Patents:	0
Applicants:	1
NDAs:	2
Bulk Api Vendors:	83
Clinical Trials:	20
Formulation / Manufacturing:	see details
DailyMed Link:	COMBIVENT at DailyMed

US Patents and Regulatory Information for COMBIVENT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	COMBIVENT	albuterol sulfate; ipratropium bromide	AEROSOL, METERED;INHALATION	020291-001	Oct 24, 1996		DISCN	No	No
Boehringer Ingelheim	COMBIVENT RESPIMAT	albuterol sulfate; ipratropium bromide	SPRAY, METERED;INHALATION	021747-001	Oct 7, 2011		RX	Yes	Yes			Y
Boehringer Ingelheim	COMBIVENT RESPIMAT	albuterol sulfate; ipratropium bromide	SPRAY, METERED;INHALATION	021747-001	Oct 7, 2011		RX	Yes	Yes			Y
Boehringer Ingelheim	COMBIVENT RESPIMAT	albuterol sulfate; ipratropium bromide	SPRAY, METERED;INHALATION	021747-001	Oct 7, 2011		RX	Yes	Yes			Y

  Purchase this report

see a sample report or, see our see our flat-rate plans

Expired US Patents for COMBIVENT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	COMBIVENT	albuterol sulfate; ipratropium bromide	AEROSOL, METERED;INHALATION	020291-001	Oct 24, 1996

  Purchase this report

see a sample report or, see our see our flat-rate plans